Drug intelligence / Profile preview

OLZOX

Development stage: Unknown
Lead developer: Lloyd Healthcare
Modality: Small Molecules
Administration: Oral

Overview

OLZOX is a generic formulation of olmesartan medoxomil, marketed by Lloyd Healthcare. It is a small molecule angiotensin II receptor blocker (ARB) indicated for the treatment of hypertension (high blood pressure) and the preservation of kidney function in patients with diabetes. By selectively blocking the binding of angiotensin II to the AT1 receptor in vascular smooth muscle and the adrenal gland, OLZOX inhibits the vasoconstrictive and aldosterone-secreting effects of angiotensin II, leading to reduced blood pressure and improved blood flow. It is typically administered orally and is available in strengths such as 20mg and 40mg.

Brand names: OLZOX
Other names: olmesartan medoxomil

Targets

AGTR1 (Angiotensin II Type-1 receptor)

Beyond the preview

Go deeper on OLZOX.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OLZOX.

Explore the full profile